Molecular therapy for Cancer: Anti-cancer drug Campothecin (CPT) suppresses the expression of oncogenic Zinc finger protein 217 (ZNF217) via down regulation of its target gene, 29/January/2015, 22.37

MiRNA-based therapy for pulmonary arterial hypertension: Apurinic/Apyrimidinic Endonuclease inhibits the development of pulmonary arterial hypertension via up regulation of its target gene, 29/November/2014, 22.32
January 29, 2015
Molecular therapy for Cancer: Tumor suppressor MiRNA miR-29c increases the expression of tumor suppressor PTEN via down regulation of its target gene, 29/January/2015, 22.41
January 29, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Molecular therapy for Cancer: Anti-cancer drug Campothecin (CPT) suppresses the expression of oncogenic Zinc finger protein 217 (ZNF217) via down regulation of its target gene, 29/January/2015, 22.37, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests that Campothecin (CPT), by increasing the expression of its target gene, it may suppress the expression of ZNF217.  Thus, pharmacological formulations encompassing “Campothecin  or its analogues  may be used to inhibit the progression of tumors.

Amount: $ 200

Undisclosed information: How Campothecin (CPT) suppresses the expression of ZNF217

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.